These are heady days for immunotherapy researchers, the scientists making progress unleashing the human immune system against lethal cancers.

Interventions once envisioned in laboratories are now treatments saving the lives of some patients struck by melanoma, kidney cancer, and lung cancer. Promise is rising for treatments against malignancies arising elsewhere as well.

With his new insights into how cancer cells use biochemical signaling to suppress our immune system, Brent Hanks, MD, PhD, is part of this translational momentum.

Susan G. Komen announced $3.6 million in research funding would go to 10 programs at Duke University and UNC-Chapel Hill.

At the Spring Faculty Meeting May 4th at the Duke Gardens, the following

Subscribe to BlobeGerard